|
Botulinum toxin type A
93094EC · aboBoNT-A
|
SNAP25, TGFB1, TRPV1 |
overactive bladder |
Allergan, Ipsen, Merz Pharmaceuticals GmbH +389 |
Approved
|
645 |
9 days ago |
|
CSB-001
|
— |
corneal disorder |
Claris Biotherapeutics, Inc. |
Phase 1/2
|
3 |
9 days ago |
|
Docetaxel
BIND-014 · CPC634
|
AR, BCL2 |
breast cancer |
National Cancer Institute (NCI), Sanofi, Aventis Pharmaceuticals +899 |
Approved
|
1576 |
9 days ago |
|
Durvalumab
durva · Durvalumab (Imfimzi)
|
CD274 |
non-small cell lung carcinoma |
AstraZeneca, National Cancer Institute (NCI), MedImmune LLC +497 |
Approved
|
729 |
9 days ago |
|
HB1801
docetaxel
|
— |
HER2 positive breast carcinoma |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Shanghai JMT-Bio Inc., Fudan University |
Phase 3
|
9 |
9 days ago |
|
KN3835
|
— |
toe, misshapen |
Endo USA Inc., a Keenova Therapeutics Company |
Phase 3
|
2 |
9 days ago |
|
Saccharomyces boulardii CNCM I-745
Saccharomyces boulardi (Sb) · S. boulardii CNCM I-745
|
— |
acute diarrhea |
Biocodex, Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Universidad San Francisco de Quito +1 |
Phase 4
|
4 |
9 days ago |
|
Subunit Influenza Vaccine
|
— |
influenza |
Ab&B Bio-tech Co., Ltd.JS, Shangyu District Center for Disease Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention |
Phase 4
|
1 |
9 days ago |
|
Tremelimumab
CP-675 · CP-675,206
|
CTLA4 |
hepatocellular carcinoma |
AstraZeneca, MedImmune LLC, National Cancer Institute (NCI) +162 |
Approved
|
245 |
9 days ago |
|
Triamcinolone Acetonide
Adcortyl · Aristocort® C
|
— |
diabetic macular edema |
National Eye Institute (NEI), Pacira Pharmaceuticals, Inc, Tanta University +177 |
Approved
|
178 |
9 days ago |
|
A/Arkansas/08/2020 (pH1N1)
|
— |
— |
National Institute of Allergy and Infectious Diseases (NIAID) |
Phase 1
|
1 |
10 days ago |
|
Acetaminophen
Abdine · Acamol
|
FAAH, TRPV1 |
patent ductus arteriosus |
GlaxoSmithKline, Mallinckrodt, Johnson & Johnson Consumer and Personal Products Worldwide +468 |
Approved
|
569 |
10 days ago |
|
Alendronic Acid
Acide alendronique · Acido alendronico
|
FDPS |
osteoporosis |
Organon and Co, Merck Sharp & Dohme LLC, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) +86 |
Approved
|
91 |
10 days ago |
|
Amitriptyline
amitriptyline HCL · amitriptyline hydrochloride
|
— |
depressive disorder |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Wright State University, Boehringer Ingelheim +68 |
Approved
|
55 |
10 days ago |
|
Ammoxetine
Ammoxetine hydrochloride
|
— |
major depressive disorder |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Phase 3
|
8 |
10 days ago |
|
Aramchol
|
SCD, CYP3A4 |
metabolic dysfunction-associated steatohepatitis |
Galmed Pharmaceuticals Ltd, Diamond Pharma Services Regulatory Affairs Consultancy, Galmed Research and Development, Ltd. +26 |
Phase 3
|
11 |
10 days ago |
|
BCD-261
|
— |
Crohn disease |
Biocad, SPH-BIOCAD (HK) Limited |
Phase 2
|
4 |
10 days ago |
|
Betamethasone
Bentelan · Betafos®
|
— |
psoriasis |
LEO Pharma, Laboratorios Silanes S.A. de C.V., Assiut University +80 |
Approved
|
74 |
10 days ago |
|
Bevacizumab
Altuzan · Avastin
|
VEGFA |
colorectal cancer |
Genentech, Inc., National Cancer Institute (NCI), Hoffmann-La Roche +1,085 |
Approved
|
2041 |
10 days ago |
|
CAL/BDP
|
— |
psoriasis |
— |
—
|
0 |
10 days ago |
|
Cal-Mag Butyrate
|
— |
cognitive disorder |
Miami VA Healthcare System, VA Office of Research and Development, VA Salt Lake City Health Care System |
Phase 2
|
1 |
10 days ago |
|
Capecitabine
5-FU · Capecitabina
|
TYMS |
colorectal cancer |
National Cancer Institute (NCI), Hoffmann-La Roche, Fudan University +883 |
Approved
|
1521 |
10 days ago |
|
Carboplatin
Carbo · Carboplatin: Carplan
|
— |
non-small cell lung carcinoma |
National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Eli Lilly and Company +1,011 |
Approved
|
1952 |
10 days ago |
|
Cisplatin
Abiplatin · cis-diamminedichloroplatinum
|
— |
non-small cell lung carcinoma |
National Cancer Institute (NCI), Sun Yat-sen University, Eli Lilly and Company +1,162 |
Approved
|
2269 |
10 days ago |
|
Colistin
colimycin (colistin) · colistimethate
|
— |
bacterial pneumonia |
Mahidol University, Ain Shams University, Andalusian Public Foundation for Health Research in Seville +39 |
Approved
|
36 |
10 days ago |
|
Dapagliflozin
A51R1 · ATB-1012
|
OTUD1, SLC5A2 |
type 2 diabetes mellitus |
AstraZeneca, Bristol-Myers Squibb, University Medical Center Groningen +386 |
Approved
|
427 |
10 days ago |
|
Disitamab Vedotin
Disitamab Vedotin （RC48-ADC) · RC48
|
ERBB2 |
gastric cancer |
RemeGen Co., Ltd., Fudan University, RenJi Hospital +82 |
Phase 4
|
131 |
10 days ago |
|
EU-Phesgo
|
— |
HER2 positive breast carcinoma |
— |
—
|
0 |
10 days ago |
|
EYE103
|
— |
diabetic macular edema |
EyeBiotech Ltd. |
Phase 2/3
|
4 |
10 days ago |
|
Etoposide
Ad2/HIF-1α/VP16 · Etopophos
|
HIF1A |
lymphoma |
National Cancer Institute (NCI), Children's Oncology Group, Memorial Sloan Kettering Cancer Center +646 |
Approved
|
918 |
10 days ago |
|
Everolimus
Afinitor® · AfinitorTM
|
HIF1A, MTOR |
breast cancer |
Novartis Pharmaceuticals, Novartis, National Cancer Institute (NCI) +474 |
Approved
|
708 |
10 days ago |
|
F182112
|
— |
refractory plasma cell neoplasm |
Shandong New Time Pharmaceutical Co., LTD, Institute of Hematology & Blood Diseases Hospital, China |
Phase 3
|
6 |
10 days ago |
|
Fludarabine
2-F-ara-AMP · 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-
|
— |
myelodysplastic syndrome |
National Cancer Institute (NCI), M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center +276 |
Approved
|
452 |
10 days ago |
|
FuFei HuaZhuo TongLuo Granule
|
— |
antisynthetase syndrome |
First People's Hospital of Hangzhou |
—
|
1 |
10 days ago |
|
HDM1002
|
— |
type 2 diabetes mellitus |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
Phase 3
|
12 |
10 days ago |
|
HLX319
|
— |
HER2 positive breast carcinoma |
Shanghai Henlius Biotech |
Phase 1
|
2 |
10 days ago |
|
IMC-002
|
— |
cancer |
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd., ImmuneOncia Therapeutics Inc., Suzhou Immunofoco Biotechnology Co., Ltd |
Phase 1/2
|
5 |
10 days ago |
|
IMM0306
amulirafusp alfa
|
CD47 |
B-cell non-Hodgkin lymphoma |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Worldwide Clinical Trials |
Phase 3
|
5 |
10 days ago |
|
JPH034
|
— |
— |
J-Pharma Co., Ltd. |
Phase 1
|
1 |
10 days ago |
|
JYP0061
|
— |
atopic eczema |
Guangzhou JOYO Pharma Co., Ltd |
Phase 2
|
3 |
10 days ago |
|
Ketorolac
Acular® · Acular LS
|
PTGS2, RAC1, CDC42 |
cataract |
Egalet Ltd, Allergan, Henry Ford Health System +200 |
Approved
|
227 |
10 days ago |
|
Leuprolide
CAMCEVI® · CKD-841
|
— |
prostate cancer |
National Cancer Institute (NCI), M.D. Anderson Cancer Center, Abbott +232 |
Approved
|
216 |
10 days ago |
|
MC2-01
calcipotriene/betamethasone dipropionate
|
— |
psoriasis |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., MC2 Therapeutics |
Phase 3
|
1 |
10 days ago |
|
Megestrol Acetate
Megace · Megace acetate
|
— |
atypical endometrial hyperplasia |
National Cancer Institute (NCI), Changchun GeneScience Pharmaceutical Co., Ltd., Fudan University +91 |
Approved
|
90 |
10 days ago |
|
Melatonin
5-methoxy-N-acetyltryptamine · BCI-049
|
NLRP3 |
sleep disorder |
Tanta University, Ain Shams University, Neurim Pharmaceuticals Ltd. +271 |
Approved
|
256 |
10 days ago |
|
Migaldendranib
D-4517.2
|
— |
diabetic macular edema |
Ashvattha Therapeutics, Inc. |
Phase 2
|
3 |
10 days ago |
|
Norepinephrine
Arterenol® · Levophed
|
— |
hypotensive disorder |
General Hospital of Ningxia Medical University, Cairo University, Mansoura University +101 |
Phase 4
|
118 |
10 days ago |
|
Oxaliplatin
205803BIJ · diaminocyclohexane-platinum
|
— |
colorectal cancer |
National Cancer Institute (NCI), Sanofi, Sun Yat-sen University +919 |
Approved
|
1746 |
10 days ago |
|
Paclitaxel
ABI-007 · Abraxane
|
TLR4 |
breast cancer |
National Cancer Institute (NCI), Bristol-Myers Squibb, M.D. Anderson Cancer Center +1,015 |
Approved
|
2049 |
10 days ago |
|
Pemetrexed
ALIMTA · Alimta (brand name for Pemetrexed)
|
GART, TYMS, DHFR |
non-small cell lung carcinoma |
Eli Lilly and Company, National Cancer Institute (NCI), Merck Sharp & Dohme LLC +403 |
Approved
|
690 |
10 days ago |